{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:37:03Z","timestamp":1783611423188,"version":"3.55.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2001,8,1]],"date-time":"2001-08-01T00:00:00Z","timestamp":996624000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2001,8]]},"DOI":"10.1007\/s11910-001-0087-6","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T12:25:37Z","timestamp":1180700737000},"page":"337-345","source":"Crossref","is-referenced-by-count":23,"title":["Focal dystonia: The role of botulinum toxin"],"prefix":"10.1007","volume":"1","author":[{"given":"Ron","family":"Tintner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"87_CR1","first-page":"513","volume-title":"Parkinson\u2019s Disease and Movement Disorders","author":"J Jankovic","year":"1998","unstructured":"Jankovic J, Fahn S: Dystonic disorders. In Parkinson\u2019s Disease and Movement Disorders, edn 3. Edited by Jankovic J, Tolosa E. Baltimore, Maryland: Williams and Wilkins; 1998:513\u2013551.","edition":"edn 3"},{"key":"87_CR2","first-page":"79","volume":"78","author":"SB Bressman","year":"1998","unstructured":"Bressman SB, de Leon DR, et al.: Clinical-genetic spectrum of primary dystonia. Adv Neurology 1998, 78:79\u201391.","journal-title":"Adv Neurology"},{"key":"87_CR3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/1531-8257(200101)16:1<7::AID-MDS1005>3.0.CO;2-0","volume":"16","author":"J Jankovic","year":"2001","unstructured":"Jankovic J: Can peripheral trauma induce dystonia and other movement disorders? Yes! Mov Disord 2001, 16:7\u201312.","journal-title":"Yes! Mov Disord"},{"key":"87_CR4","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0894-1130(00)80022-8","volume":"13","author":"NN Byl","year":"2000","unstructured":"Byl NN, McKenzie A, Nagarajan SS: Differences in somatosensory hand organization in a healthy flutist and a flutist with focal hand dystonia: a case report. J Hand Ther 2000, 13:302\u2013309.","journal-title":"J Hand Ther"},{"key":"87_CR5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/1531-8257(199903)14:2<295::AID-MDS1015>3.0.CO;2-J","volume":"14","author":"KS Topp","year":"1999","unstructured":"Topp KS, Byl NN: Movement dysfunction following repetitive hand opening and closing: anatomical analysis in Owl monkeys. Mov Disord 1999, 14:295\u2013306. Stereotypical hand squeezing resulted in a task-specific movement dysfunction in two monkeys, along with reorganization of the representation of the hand on the contralateral somatosensory cortex (area 3b). This suggests that repetitive, stereotypical motor behaviors can lead to motor control problems without local inflammation.","journal-title":"Mov Disord"},{"key":"87_CR6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1017\/S0317167100052240","volume":"27","author":"PK Pal","year":"2000","unstructured":"Pal PK, Samii A, Schulzer M, et al.: Head tremor in cervical dystonia. Can J Neurol Sci 2000, 27:137\u2013142.","journal-title":"Can J Neurol Sci"},{"key":"87_CR7","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/mds.870120411","volume":"12","author":"G Deuschl","year":"1997","unstructured":"Deuschl G, Heinen F, Guschlbauer B, et al.: Hand tremor in patients with spasmodic torticollis. Mov Disord 1997, 12:547\u2013552.","journal-title":"Mov Disord"},{"key":"87_CR8","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/brain\/121.7.1195","volume":"121","author":"A Berardelli","year":"1998","unstructured":"Berardelli A, Rothwell JC, Hallett M, et al.: The pathophysiology of primary dystonia. Brain 1998, 121:1195\u20131212. Excellent review of the basic and clinical aspects of primary dystonia.","journal-title":"Brain"},{"key":"87_CR9","first-page":"169","volume":"78","author":"J Jankovic","year":"1998","unstructured":"Jankovic J: Medical therapy and botulinum toxin in dystonia. Adv Neurol 1998, 78:169\u2013183.","journal-title":"Adv Neurol"},{"key":"87_CR10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0300-9084(00)00216-9","volume":"82","author":"Y Humeau","year":"2000","unstructured":"Humeau Y, Doussau F, Grant NJ, Poulain B: How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 2000, 82:427\u2013446.","journal-title":"Biochimie"},{"key":"87_CR11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1067\/mjd.2000.105567","volume":"43","author":"W Huang","year":"2000","unstructured":"Huang W, Foster JA, Rogachefsky AS: Pharmacology of botulinum toxin. J Am Acad Dermatol 2000, 43:249\u2013259.","journal-title":"J Am Acad Dermatol"},{"key":"87_CR12","first-page":"718","volume":"80","author":"G Schiavo","year":"2000","unstructured":"Schiavo G, Matteoli M, Montecucco C: Neurotoxins affecting neuroexocytosis. Physiolog Rev 2000, 80:718\u2013766. Excellent recent review of the mechanism of action of botulinum toxin and other related neurotoxins.","journal-title":"Physiolog Rev"},{"key":"87_CR13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0022-510X(97)00151-2","volume":"152","author":"N Giladi","year":"1997","unstructured":"Giladi N: The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J Neurol Sci 1997, 152:132\u2013135.","journal-title":"J Neurol Sci"},{"key":"87_CR14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1017\/S0012162200000220","volume":"42","author":"S Barwood","year":"2000","unstructured":"Barwood S, Baillieu C, Boyd R, et al.: Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial. Dev Med Child Neurol 2000, 42:116\u2013121.","journal-title":"Dev Med Child Neurol"},{"key":"87_CR15","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0006-2952(00)00260-4","volume":"59","author":"J Purkiss","year":"2000","unstructured":"Purkiss J, Welch M, Doward S, Foster K: Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 2000, 59:1403\u20131406.","journal-title":"Biochem Pharmacol"},{"key":"87_CR16","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/archneur.57.8.1190","volume":"57","author":"CH Kwak","year":"2000","unstructured":"Kwak CH, Hanna PA, Jankovic J: Botulinum toxin in the treatment of tics. Arch Neurol 2000, 57:1190\u20131203.","journal-title":"Arch Neurol"},{"key":"87_CR17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/1531-8249(200007)48:1<20::AID-ANA5>3.0.CO;2-U","volume":"48","author":"F Gilio","year":"2000","unstructured":"Gilio F, Curra A, Lorenzano C, et al.: Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia. Ann Neurol 2000, 48:20\u201326. These data strongly suggest that botulinum toxin can transiently alter the excitability of the cortical motor areas by reorganizing the inhibitory and excitatory intracortical circuits, although this is probably through peripheral mechanisms.","journal-title":"Ann Neurol"},{"key":"87_CR18","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/1097-4598(200009)23:9<1313::AID-MUS1>3.0.CO;2-U","volume":"23","author":"K Kaji","year":"2000","unstructured":"Kaji K: Facts and fancies on writer\u2019s cramp. Muscle & Nerve 2000, 23:1313\u20131315.","journal-title":"Muscle & Nerve"},{"key":"87_CR19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/1531-8249(200007)48:1<7::AID-ANA2>3.0.CO;2-O","volume":"48","author":"M Hallett","year":"2000","unstructured":"Hallett M: How does botulinum toxin work? Ann Neurol 2000, 48:7\u20138.","journal-title":"Ann Neurol"},{"key":"87_CR20","first-page":"231","volume":"78","author":"PY Bergh Van den","year":"1998","unstructured":"Van den BerghPY, Lison DF: Dose standardization of botulinum toxin. Adv Neurol 1998, 78:231\u2013235.","journal-title":"Adv Neurol"},{"key":"87_CR21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/jnnp.64.1.6","volume":"64","author":"T Odergren","year":"1998","unstructured":"Odergren T, Hjaltason H, Kaakkola S, et al.: A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998, 64:6\u201312.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"87_CR22","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/mds.870120627","volume":"12","author":"C Sampaio","year":"1997","unstructured":"Sampaio C, Ferreira JJ, Simoes F, et al.: DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A\u2014Dysport and Botox\u2014assuming a ratio of 4:1. Mov Disord 1997, 12:1013\u20131018.","journal-title":"Mov Disord"},{"key":"87_CR23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.49.1.189","volume":"49","author":"RR Sloop","year":"1997","unstructured":"Sloop RR, Cole BA, Escutin RO: Human response to botulinum toxin injection: type B compared with type A. Neurology 1997, 49:189\u2013194.","journal-title":"Neurology"},{"key":"87_CR24","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1212\/WNL.37.4.616","volume":"37","author":"J Jankovic","year":"1987","unstructured":"Jankovic J, Orman J: Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987, 37:616\u2013623.","journal-title":"Neurology"},{"key":"87_CR25","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/jnnp.53.8.633","volume":"53","author":"J Jankovic","year":"1990","unstructured":"Jankovic J, Schwartz K, Donovan DT: Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990, 53:633\u2013639.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"87_CR26","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1212\/WNL.43.4.834","volume":"43","author":"J Jankovic","year":"1993","unstructured":"Jankovic J, Schwartz KS: Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology 1993, 43:834\u2013836.","journal-title":"Neurology"},{"key":"87_CR27","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0161-6420(97)30220-6","volume":"104","author":"J Price","year":"1997","unstructured":"Price J, Farish S, Taylor H, O\u2019Day J: Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections. Ophthalmology 1997, 104:865\u2013868.","journal-title":"Ophthalmology"},{"key":"87_CR28","first-page":"686","volume":"10","author":"J Jankovic","year":"1995","unstructured":"Jankovic J: Apraxia of lid opening. Mov Disord 1995, 10:686\u2013687.","journal-title":"Mov Disord"},{"key":"87_CR29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/eye.2000.86","volume":"14","author":"IA Mackie","year":"2000","unstructured":"Mackie IA: Riolan\u2019s muscle: action and indications for botulinum toxin injection. Eye. 2000, 14:347\u2013352.","journal-title":"Eye."},{"key":"87_CR30","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1212\/WNL.53.9.2102","volume":"53","author":"EK Tan","year":"1999","unstructured":"Tan EK, Jankovic J: Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology 1999, 53:2102\u20132107. Results of long-term experience with botulinum toxin-A (BTX-A) for oromandibular dystonia in large number of patients. BTX-A is clearly effective in about 75% of people; however, those with jaw-opening dystonias do somewhat worse than jaw-closing dystonias.","journal-title":"Neurology"},{"key":"87_CR31","first-page":"429","volume-title":"Therapy with botulinum toxin","author":"M Brin","year":"1994","unstructured":"Brin M, Blitzer A, Herman S, Steward C: Oromandibular dystonia: treatment of 96 cases with botulinum A. In Therapy with botulinum toxin. Edited by Jankovic J, Hallett M. New York: Marcel Dekker; 1994:429\u2013435."},{"key":"87_CR32","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1080\/08869634.1999.11746095","volume":"17","author":"MW Watts","year":"1999","unstructured":"Watts MW, Tan EK, Jankovic J: Bruxism and cranial-cervical dystonia: is there a relationship? Craniology 1999, 17:196\u2013201.","journal-title":"Craniology"},{"key":"87_CR33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.14219\/jada.archive.2000.0149","volume":"131","author":"EK Tan","year":"2000","unstructured":"Tan EK, Jankovic J: Treating severe bruxism with botulinum toxin. J Am Dent Assoc 2000, 131:211\u2013216. Review of clinical experience using botulinum toxin for severe bruxism.","journal-title":"J Am Dent Assoc"},{"key":"87_CR34","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/00005537-199810000-00003","volume":"108","author":"A Blitzer","year":"1998","unstructured":"Blitzer A, Brin MF, Stewart CF: Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope 1998, 108:1435\u20131441.","journal-title":"Laryngoscope"},{"key":"87_CR35","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/000348949810700403","volume":"107","author":"TP Langeveld","year":"1998","unstructured":"Langeveld TP, Drost HA, Baatenburg de Jong RJ: Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 1998, 107:280\u2013284.","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"87_CR36","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S0030-6665(05)70249-8","volume":"33","author":"SR Gibbs","year":"2000","unstructured":"Gibbs SR, Blitzer A: Botulinum toxin for the treatment of spasmodic dysphonia. Otolaryngol Clin North Am 2000, 33:879\u2013894. Comprehensive review describing the authors\u2019 treatment paradigm and experience in treating over 900 patients with botulinum toxin for patients with laryngeal dystonia.","journal-title":"Otolaryngol Clin North Am"},{"key":"87_CR37","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/brain\/121.4.547","volume":"121","author":"WT Dauer","year":"1998","unstructured":"Dauer WT, Burke RE, Greene P, Fahn S: Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain 1998, 121:547\u2013560. Excellent recent review of the basic and clinical aspects of cervical dystonia.","journal-title":"Brain"},{"issue":"suppl 5","key":"87_CR38","first-page":"S15","volume":"55","author":"CL Comella","year":"2000","unstructured":"Comella CL, Jankovic J, Brin MF: Use of botulinum toxin type A in the treatment of cervical dystonia. Neurology. 2000, 55(suppl 5):S15-S21. Comprehensive recent review of all aspects of botulinum toxin in cervical dystonia.","journal-title":"Neurology."},{"key":"87_CR39","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/jnnp.68.4.465","volume":"68","author":"SJ Chawda","year":"2000","unstructured":"Chawda SJ, Munchau A, Johnson D, et al.: Pattern of premature degenerative changes of the cervical spine in patients with spasmodic torticollis and the impact on the outcome of selective peripheral denervation. J Neurol Neurosurg Psychiatry 2000, 68:465\u2013471.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"87_CR40","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ana.410290407","volume":"29","author":"DJ Gelb","year":"1991","unstructured":"Gelb DJ, Yoshimura DM, Olney RK, et al.: Change in pattern of muscle activity following botulinum toxin injections for torticollis. Ann Neurol 1991, 29:370\u2013376.","journal-title":"Ann Neurol"},{"key":"87_CR41","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/S1388-2457(99)00127-3","volume":"110","author":"J Erdal","year":"1999","unstructured":"Erdal J, Ostergaard L, Fuglsang-Frederiksen A, et al.: Long-term botulinum toxin treatment of cervical dystonia\u2014EMG changes in injected and noninjected muscles. Clin Neurophysiol 1999, 110:1650\u20131654.","journal-title":"Clin Neurophysiol"},{"key":"87_CR42","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1212\/WNL.42.4.878","volume":"42","author":"CL Comella","year":"1992","unstructured":"Comella CL, Buchman AS, Tanner CM, et al.: Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology 1992, 42:878\u2013882.","journal-title":"Neurology"},{"key":"87_CR43","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/1097-4598(200011)23:11<1752::AID-MUS12>3.0.CO;2-U","volume":"23","author":"JA Gerpen Van","year":"2000","unstructured":"Van GerpenJA, Matsumoto JY, Ahlskog JE, et al.: Utility of an EMG mapping study in treating cervical dystonia. Muscle Nerve 2000, 23:1752\u20131756.","journal-title":"Muscle Nerve"},{"key":"87_CR44","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1212\/WNL.40.8.1213","volume":"40","author":"P Greene","year":"1990","unstructured":"Greene P, Kang U, Fahn S, et al.: Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990, 40:1213\u20131218.","journal-title":"Neurology"},{"key":"87_CR45","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s004150050345","volume":"246","author":"KR Kessler","year":"1999","unstructured":"Kessler KR, Skutta M, Benecke R: Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 1999, 246:265\u2013274. Large-scale study of patients suffering from idiopathic cervical dystonia demonstrating the efficacy and safety of treatment with botulinum neurotoxin type A.","journal-title":"J Neurol"},{"issue":"suppl 5","key":"87_CR46","first-page":"S29","volume":"55","author":"MF Lew","year":"2000","unstructured":"Lew MF, Brashear A, Factor S: The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three clinical trials. Neurology 2000, 55(suppl 5):S29-S35. Botulinum toxin type B was recently released for clinical use. This paper reviews all three prior studies studies addressing efficacy and safety for cervical dystonia.","journal-title":"Neurology"},{"key":"87_CR47","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1212\/WNL.53.7.1439","volume":"53","author":"A Brashear","year":"1999","unstructured":"Brashear A, Lew MF, Dykstra DD, et al.: Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999, 53:1439\u20131446.","journal-title":"Neurology"},{"key":"87_CR48","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1212\/WNL.53.7.1431","volume":"53","author":"MF Brin","year":"1999","unstructured":"Brin MF, Lew MF, Adler CH, et al.: Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999, 53:1431\u20131438.","journal-title":"Neurology"},{"key":"87_CR49","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1212\/WNL.49.3.701","volume":"49","author":"MF Lew","year":"1997","unstructured":"Lew MF, Adornato BT, Duane DD, et al.: Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997, 49:701\u2013707.","journal-title":"Neurology"},{"key":"87_CR50","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1177\/014107689208500906","volume":"85","author":"T Anderson","year":"1992","unstructured":"Anderson T, Rivest J, Stell R, et al.: Botulinum toxin treatment of spasmodic torticollis. J Roy Soc Med 1992, 85:524\u2013529.","journal-title":"J Roy Soc Med"},{"key":"87_CR51","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1212\/WNL.42.7.1307","volume":"42","author":"CL Comella","year":"1992","unstructured":"Comella CL, Tanner CM, DeFoor-Hill L, Smith C: Dysphagia after botulinum toxin injections for spasmodic torticollis: clinical and radiologic findings. Neurology 1992, 42:1307\u20131310.","journal-title":"Neurology"},{"key":"87_CR52","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/hed.2880140108","volume":"14","author":"GE Borodic","year":"1992","unstructured":"Borodic GE, Pearce LB, Smith K, Joseph M: Botulinum a toxin for spasmodic torticollis: multiple vs single injection points per muscle. Head Neck 1992, 14:33\u201337.","journal-title":"Head Neck"},{"key":"87_CR53","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/WNL.46.4.1066","volume":"46","author":"JW Brans","year":"1996","unstructured":"Brans JW, Lindeboom R, Snoek JW, et al.: Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 1996, 46:1066\u20131072.","journal-title":"Neurology"},{"key":"87_CR54","first-page":"267","volume-title":"Therapy with Botulinum Toxin","author":"W Poewe","year":"1994","unstructured":"Poewe W, Wissel J: Experience with botulinum toxin in cervical dystonia. In Therapy with Botulinum Toxin. Edited by Jankovic J, Hallet M. New York: Marcel Dekker; 1994:267\u2013278."},{"key":"87_CR55","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/jnnp.64.1.13","volume":"64","author":"W Poewe","year":"1998","unstructured":"Poewe W, Deuschl G, Nebe A, et al.: What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry 1998, 64:13\u201317. Determining optimal dosing of botulinum toxin is an ongoing issue. This large dose-ranging study establishes data to advocate starting at relatively small doses (100 Dysport U), although higher doses (1000 U) do give somewhat greater and longer duration effects.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"87_CR56","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/mds.870130318","volume":"13","author":"D Tarsy","year":"1998","unstructured":"Tarsy D: Comparison of acute- and delayed-onset posttraumatic cervical dystonia. Mov Disord 1998, 13:481\u2013485. Details the syndrome of acute-onset post-traumatic cervical dystonia and its relative resistance to botulinum toxin.","journal-title":"Mov Disord"},{"key":"87_CR57","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/0363-5023(93)90060-G","volume":"18","author":"J Jankovic","year":"1993","unstructured":"Jankovic J, Schwartz KS: Use of botulinum toxin in the treatment of hand dystonia. J Hand Surg [Am]. 1993, 18:883\u2013887.","journal-title":"J Hand Surg [Am]."},{"key":"87_CR58","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archneur.1996.00550070055012","volume":"53","author":"SL Pullman","year":"1996","unstructured":"Pullman SL, Greene P, Fahn S, Pedersen SF: Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients. Arch Neurol 1996, 53:617\u2013624.","journal-title":"Arch Neurol"},{"key":"87_CR59","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/(SICI)1097-4598(199705)20:5<593::AID-MUS8>3.0.CO;2-4","volume":"20","author":"MH Ross","year":"1997","unstructured":"Ross MH, Charness ME, Sudarsky L, Logigian EL: Treatment of occupational cramp with botulinum toxin: diffusion of toxin to adjacent noninjected muscles. Muscle Nerve 1997, 20:593\u2013598.","journal-title":"Muscle Nerve"},{"key":"87_CR60","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/mds.870110306","volume":"11","author":"J Jankovic","year":"1996","unstructured":"Jankovic J, Schwartz K, Clemence W, et al.: A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord 1996, 11:250\u2013256.","journal-title":"Mov Disord"},{"key":"87_CR61","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/mds.870120516","volume":"12","author":"J Wissel","year":"1997","unstructured":"Wissel J, Masuhr F, Schelosky L, et al.: Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor. Mov Disord 1997, 12:722\u2013726.","journal-title":"Mov Disord"},{"key":"87_CR62","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1097\/00005537-200008000-00028","volume":"110","author":"P Warrick","year":"2000","unstructured":"Warrick P, Dromey C, Irish JC, et al.: Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection. Laryngoscope 2000, 110:1366\u20131374. Using objective acoustic measures, only a small proportion of patients achieved benefit from botulinum toxin A injection for essential voice tremor; however, the majority of patients described a subjective reduction in vocal effort.","journal-title":"Laryngoscope"},{"key":"87_CR63","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1212\/WNL.46.1.26","volume":"46","author":"G Borodic","year":"1996","unstructured":"Borodic G, Johnson E, Goodnough M, Schantz E: Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 1996, 46:26\u201329.","journal-title":"Neurology"},{"key":"87_CR64","first-page":"337","volume":"22","author":"BA Racette","year":"1999","unstructured":"Racette BA, McGee-Minnich L, Perlmutter JS: Efficacy and safety of a new bulk toxin of botulinum toxin in cervical dystonia: a blinded evaluation. Clin Neuropharmacol 1999, 22:337\u2013339.","journal-title":"Clin Neuropharmacol"},{"key":"87_CR65","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1212\/WNL.50.6.1624","volume":"50","author":"PA Hanna","year":"1998","unstructured":"Hanna PA, Jankovic J: Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology 1998, 50:1624\u20131629.","journal-title":"Neurology"},{"key":"87_CR66","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1212\/WNL.50.5.1463","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Nairne A, Hyman N, et al.: A radioimmuno-precipitation assay for antibodies to botulinum A. Neurology. 1998, 50:1463\u20131466.","journal-title":"Neurology."},{"key":"87_CR67","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1136\/jnnp.66.5.612","volume":"66","author":"PA Hanna","year":"1999","unstructured":"Hanna PA, Jankovic J, Vincent A: Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry 1999, 66:612\u2013616. This study addresses the issue of the best method to determine immunoresistance to botulinum toxin and presents an algorithm for approaching secondary treatment resistance.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"87_CR68","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/archotol.126.4.533","volume":"126","author":"ME Smith","year":"2000","unstructured":"Smith ME, Ford CN: Resistance to botulinum toxin injections for spasmodic dysphonia. Arch Otolaryngol Head Neck Surg 2000, 126:533\u2013535.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"87_CR69","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000008121","volume":"43","author":"JD Rollnik","year":"2000","unstructured":"Rollnik JD, Matzke M, Wohlfarth K, et al.: Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study. Eur Neurol 2000, 43:9\u201312. When Dysport was diluted to less than half the recommended concentration with albumin (25 units\/mL), substantially lower doses could be used with excellent efficacy but with lower side effects relative to historic controls. This does not necessarily apply to Botox.","journal-title":"Eur Neurol"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-001-0087-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-001-0087-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-001-0087-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T04:03:53Z","timestamp":1683864233000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-001-0087-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,8]]}},"alternative-id":["87"],"URL":"https:\/\/doi.org\/10.1007\/s11910-001-0087-6","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,8]]}}}